Mylan Prepares To Launch Insulin Glargine After Another Lantus IP Win

IPR Victory In US Follows Favorable District Court Ruling In March

 
• By David Wallace
  
Lantus_Glargine
Mylan is ready to launch a US Lantus rival upon FDA approval • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

More from Generics Bulletin